Cardiomyocytes are responsible for the heart's essential functions, including synchronised electrical conduction, excitation-contraction coupling, and the mechanical force generation required to drive the pumping action of the myocardium. Thus, cardiomyocytes are critical for toxicology research and modelling life-threatening cardiac diseases like hypertrophic cardiomyopathy and cardiovascular disorders, such as long QT syndrome.
Historically, cardiovascular disease modelling relied on animal models, but species-specific differences in beat rates and repolarisation currents frequently fail to reliably predict human responses. Primary human cardiomyocytes are equally challenging, typically sourced from surgical discards or non-transplantable organs, their use is severely hampered by limited availability, quality, and high donor variability. Immortalised cell lines (such as H9c2, HL-1, and AC16) suffer from similar limitations, lacking electrophysiological maturity and remaining prone to genetic instability.
Human iPSC-derived cardiomyocytes overcome these limitations, providing an accessible, physiologically relevant source. Moreover, recognising their predictive accuracy, the Comprehensive In Vitro Proarrhythmia Assay (CiPA) initiative explicitly proposes integrating human iPSC-derived ventricular cardiomyocytes into international guidelines to improve the assessment of proarrhythmic risk. Human iPSC-derived cells offer a highly reliable model for CiPA-aligned electrophysiology studies, enabling cardiotoxicity assessment.